Loading...
Market
What will be Sarepta Therapeutics' revenue from Elevidys by end of 2024?
5
Resolution / Starting Odds
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Sarepta Therapeutics' annual financial report
Story
FDA Expands Approval of Sarepta's Elevidys Gene Therapy for Duchenne Muscular Dystrophy for Ages 4 and Above
Jun 20, 2024, 09:44 PM
The U.S. Food and Drug Administration (FDA) has expanded the approval of Sarepta Therapeutics' gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD) patients aged four and above. The expanded approval now includes both ambulatory and non-ambulatory patients, with the non-ambulatory indication under accelerated approval and the ambulatory indication converted to full approval. This decision allows nearly all children suffering from DMD, a rare condition that can leave infants unable to walk, to access the treatment. Elevidys targets patients with a confirmed mutation in the DMD gene.
View original story
Similar markets
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Less than $10 billion • 25%
$10 billion to $20 billion • 25%
$20 billion to $30 billion • 25%
More than $30 billion • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Less than $500 million • 25%
$500 million - $700 million • 25%
$700 million - $900 million • 25%
More than $900 million • 25%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Stock price up 0-10% • 33%
Stock price up 10-20% • 33%
Stock price up more than 20% • 34%
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
